Background Cancer patients are at higher risk of infection and severity of Coronavirus Disease-19 (COVID-19). Management of patients infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is challenging due to the scarce scientific information and treatment guidelines. In this work, we present our Institutional experience with our first 100 patients with oncological malignancies and COVID-19. Patients and methods We conducted a cross-sectional study of the first 100 patients hospitalised at the Instituto Nacional de Enfermedades Neoplasicas (Lima, Peru) who were positive for SARS-CoV-2 by reverse transcriptase (RT)-PCR during the period 30 March to 20 June. Clinicopathological variables of the oncological disease as well as risk factors, management and outcomes to COVID-19 were evaluated. Results The mean age was 43.5 years old (standard deviations: ±24.8) where 57% were male patients. In total, 44%, 37% and 19% were adult patients bearing solid tumours, adults with haematologic malignancies and paediatric patients, respectively. Hypertension was the most frequent comorbidity (23%) followed by chronic lung disease (10%). COVID-19-associated symptoms included cough (65%), fever (57%) and dyspnoea (56%). Twelve percent of patients were asymptomatic. Nosocomial infections were more frequent in paediatric patients (84.2%) than in adult patients (16.0%). Patients with uncontrolled oncological disease were most frequent (72%). Anaemia was present in 67% of patients, 68% had lymphopenia, 62% had ferritin value > 500 mcg/L, 85% had elevated lactate dehydrogenase (LDH), 83% D-dimer > 500 ng/mL and 80% C-Reactive Protein > 8 mg/L. The most common complication was acute respiratory failure (42%). Overall fatality rate was 39% where the main cause of mortality was acute respiratory distress syndrome (64.1%). Conclusion Paediatric patients had better outcomes than adult populations, and a high number of asymptomatic carriers and nosocomial infection, early diagnosis are recommended. Considering oncological treatments 30 days before COVID-19 diagnosis, our data did not reveal an increased mortality.
【저자키워드】 COVID-19, SARS-CoV-2, Mortality, Cancer, 【초록키워드】 Treatment, coronavirus, Risk factors, Respiratory failure, cross-sectional, severity, Infection, LDH, Lung disease, Comorbidity, D-dimer, ferritin, Asymptomatic carrier, Symptom, outcome, cough, treatment guidelines, lymphopenia, early diagnosis, Asymptomatic, management, Fever, male, Patient, COVID-19 diagnosis, Nosocomial infection, age, information, disease, patients, Dyspnoea, acute respiratory distress, malignancy, Tumours, acute respiratory syndrome, higher risk, syndrome, Fatality rate, increased mortality, positive, transcriptase, elevated lactate dehydrogenase, variable, hospitalised, populations, paediatric patients, Result, evaluated, conducted, haematologic malignancy, paediatric patient, 【제목키워드】 cross-sectional,